RetinaCME
VIDEOCMEABO MOC

Examining the Impact of Early Treatment and Injection Protocol Selection on Outcomes in Diabetic Retinopathy

Author(s)/Faculty: John W. Kitchens, MD; W. Lloyd Clark, MD
Release Date: 12/31/2020Expiration Date: 12/30/2021
Credit Type: CME / ABO MOCNumber of Credits: 0.75
Content Type: VideoProvider:
The utilization of intravitreal anti-vascular endothelial growth factor (VEGF) therapies as early intervention in diabetic retinopathy (DR) has provided reduced vision-threatening complications and significant slowing of disease progression for these patients. With the potential to delay disease progression and enhance quality-of-life measures in patients with DR, optimal integration of anti-VEGF therapies into current treatment protocols is imperative. Within this CME activity, experts in the field review the latest clinical data assessing the efficacy of anti-VEGF therapy in DR, as well as evaluate current therapeutic regimens for their ability to achieve regression of DR.